Navigation Links
Plicera in Medical Technology

Amicus Therapeutics Presents Positive Results From Phase 1 Clinical Studies of Plicera for Gaucher Disease

Phase 2 Clinical Trials Initiated CRANBURY, N.J., March 21, 2007 /PRNewswire/ -- Amicus Therapeutics, a biopharmaceutical company developing small molecule, orally-administered pharmacological chaperones for the treatment of a range of human genetic diseases, announced today that it will present p...

Amicus Therapeutics Commences Phase 3 Trial Evaluating Amigal(TM) for the Treatment of Fabry Disease

...olly-owned subsidiary of Shire plc, to jointly develop Amicus' three lead pharmacological chaperone compounds for lysosomal storage disorders, Amigal, plicera and AT2220. Under the terms of the collaboration Shire will pay development and sales milestones up to a maximum of $390 million, and will also pay ti...

Amicus Therapeutics Announces Issuance of New Plicera(TM) Composition of Matter Patent

...trengthens our protection in the United States for plicera in Gaucher and is one example of our ongoing effor...armacological chaperone technology platform." plicera is currently being studied in an ongoing Phase 2 s...e third quarter of 2009. Amicus is developing plicera as part of a strategic collaboration with Shire Hu...

Amicus Therapeutics Suspends Enrollment for Phase 2 Clinical Trial of AT2220 for Pompe Disease

... medical needs. Amicus has completed Phase 2 clinical trials of Amigal for the treatment of Fabry disease and is conducting Phase 2 clinical trials of plicera for the treatment of Gaucher disease and AT2220 for the treatment of Pompe disease. Forward-Looking Statements This press release contain...

Amicus Therapeutics Announces Positive Progress of Three Lead Clinical Programs and General Outlook for 2009

...he dose and regimen for the Phase 3 studies. plicera (TM) (isofagomine tartrate) for the treatment of Gaucher Disease A Phase 2 clinical trial of plicera in Gaucher patients is ongoing. This 6 month study...er Shire HGT to prepare for Phase 3 development of plicera pending the results of the ongoing Phase 2 trial. ...

Amicus Therapeutics Announces Second Quarter 2008 Financial Results

... for the ongoing 6-month Phase 2 clinical trial of plicera in patients naive to ERT to include modified doses... The Company has modified its development plan for plicera to include a study of the pharmacokinetics of plicera in Gaucher patients. In addition, the company no l...

Amicus Therapeutics Presents Preclinical Data from Studies of Plicera for Gaucher Disease

...Nashville, TN. The data demonstrate the ability of plicera to increase levels of the target enzyme in cells d...l data from both studies will also be presented. plicera is designed to selectively bind to and stabilize G... The following is a summary of the preclinical plicera data being presented at ACMG. - In vitro ex...
Plicera in Biological Technology

Amicus Therapeutics Announces Second Quarter 2009 Financial Results

...rldwide will participate in this trial. plicera (TM) (afegostat tartrate) for the treatment of ...inical trial of the Company's investigational drug plicera is ongoing. This 6-month study is designed to eval..., Shire HGT, to prepare for Phase 3 development of plicera pending the results of the ongoing Phase 2 trial. ...

Publication of Shire plc's Annual Report 2008

...IGAL and AT2220, in markets outside the US. plicera (HGT-3410 for the treatment of Gaucher disease) plicera is an orally-administered, small molecule pharmaco...port the previously reported interim findings that plicera was generally safe and well tolerated at all doses...

Amicus Therapeutics Announces Change to Board of Directors

... medical needs. Amicus has completed Phase 2 clinical trials of Amigal for the treatment of Fabry disease and is conducting Phase 2 clinical trials of plicera for the treatment of Gaucher disease and AT2220 for the treatment of Pompe disease. FOLD-G ...

Amicus Therapeutics Announces Fourth Quarter and Full Year 2008 Financial Results

... be available in the first quarter of 2009. plicera (TM) (isofagomine tartrate) for the treatment o...on executing its ongoing Phase 2 clinical trial of plicera in Gaucher disease. This 6-month study is designed..., Shire HGT, to prepare for Phase 3 development of plicera pending the results of the ongoing Phase 2 trial. ...

Amicus Therapeutics Announces Fourth Quarter and Year End 2008 Financial Results Release Date

... medical needs. Amicus has completed Phase 2 clinical trials of Amigal for the treatment of Fabry disease and is conducting Phase 2 clinical trials of plicera for the treatment of Gaucher disease and AT2220 for the treatment of Pompe disease. FOLD -G ...

Amicus Therapeutics Adds Sol J. Barer, Ph.D. to Board of Directors

...medical needs. Amicus has completed Phase 2 clinical trials of Amigal for the treatment of Fabry disease and is conducting Phase 2 clinical trials of plicera for the treatment of Gaucher disease and AT2220 for the treatment of Pompe disease. FOLD-G ...

Amicus Therapeutics Announces Third Quarter 2008 Financial Results

...ucher disease. As previously disclosed, a 6-month Phase 2 clinical trial of plicera in patients naive to ERT is ongoing and Amicus expects the results of this ...harmacological chaperone compounds for lysosomal storage disorders, Amigal, plicera and AT2220. In this collaboration, valued at up to $440 million including a...

Shire Delivers Strong Quarter: Driven by $243m of New Product Sales (+164% YOY Growth). Revenue Guidance Upgrade.

...s Phase 2 trial support the previously reported interim findings that plicera was generally safe and well tolerated at all doses and increased target enzyme activity levels in a majority of patients. Shire has rights to plicera in markets outside the US. HGT-3510 - Pompe disease - In June 2008 Ami...

Amicus Therapeutics Announces First Quarter 2008 Financial Results

...macological chaperone Plicera. Results showed that plicera was generally safe and well tolerated at all doses...protocol for the 6-month Phase 2 clinical trial of plicera patients naive to ERT to include modified doses an...compounds for lysosomal storage disorders, Amigal, plicera and AT2220. In this collaboration valued at up to ...

Following a Good Start to the Year Shire Reaffirms Full Year 2008 Financial Guidance

...ine) METAZYM(TM) (arylsulfatase-A) MEZAVANT(R) (mesalazine) PENTASA (mesalamine) (trademark of Ferring) plicera (isofagomine tartrate) (trademark of Amicus) RAZADYNE (galantamine) (trademark of Johnson & Johnson ...
Other Tags
(Date:7/12/2014)... rise in the number of mobility devices around the ... suit the upsurge. Virtualization has become a growing trend ... The data traffic has increased by several folds with ... in larger and more complex networks. These global factors ... , The North American (NA) region is expected to ...
(Date:7/12/2014)... In this cognitive assessment ... and training’ is defined as solution that ... enhance cognitive functions. These solutions are applied ... screening, clinical trials, driver’s safety, rehabilitation, academic ... brain training, and employers’ assessment and training ...
(Date:7/12/2014)... York, New York (PRWEB) July 12, 2014 ... liver damage allegations continue to move forward in ... Court, Eastern District of Pennsylvania, Bernstein Liebhard LLP ... 2014, U.S. District Judge Lawrence F. Stengel has ... Among other things, Judge Stengel found that the ...
(Date:7/12/2014)... PA (PRWEB) July 12, 2014 "The second ... it’s uncomfortable and painful to wear shoes," said an inventor ... special sock that prevents this from happening. , He then ... effective way to prevent the second and big toes from ... endurance while wearing shoes. Ergonomic and easy to use, it's ...
(Date:7/12/2014)... York (PRWEB) July 12, 2014 As ... move forward in U.S. courts, Bernstein Liebhard LLP notes ... metal ion levels to the failure of metal-on-metal hip ... issue of The Journal of Bone & Joint Surgery, ... unilateral Articular Surface Replacement prostheses at least twelve months ...
Breaking Medicine News(10 mins):Health News:North America Software Defined Network (SDN) Market Worth $1,443.8 Million by 2019 - New Report by MicroMarket Monitor 2Health News:North America Software Defined Network (SDN) Market Worth $1,443.8 Million by 2019 - New Report by MicroMarket Monitor 3Health News:North America Software Defined Network (SDN) Market Worth $1,443.8 Million by 2019 - New Report by MicroMarket Monitor 4Health News:North America Software Defined Network (SDN) Market Worth $1,443.8 Million by 2019 - New Report by MicroMarket Monitor 5Health News:Global Cognitive Assessment & Training Market: 27.3% CAGR to 2018 Says a New Research Report Available at LifeScienceIndustryResearch.com 2Health News:Global Cognitive Assessment & Training Market: 27.3% CAGR to 2018 Says a New Research Report Available at LifeScienceIndustryResearch.com 3Health News:Global Cognitive Assessment & Training Market: 27.3% CAGR to 2018 Says a New Research Report Available at LifeScienceIndustryResearch.com 4Health News:Global Cognitive Assessment & Training Market: 27.3% CAGR to 2018 Says a New Research Report Available at LifeScienceIndustryResearch.com 5Health News:Tylenol Lawsuit News: U.S. District Judge Overseeing Federal Tylenol Liver Damage Litigation Orders Deposition of Former McNeil President, Bernstein Liebhard LLP Reports 2Health News:Tylenol Lawsuit News: U.S. District Judge Overseeing Federal Tylenol Liver Damage Litigation Orders Deposition of Former McNeil President, Bernstein Liebhard LLP Reports 3Health News:Tylenol Lawsuit News: U.S. District Judge Overseeing Federal Tylenol Liver Damage Litigation Orders Deposition of Former McNeil President, Bernstein Liebhard LLP Reports 4Health News:DePuy Pinnacle Hip Lawsuit News: Bernstein Liebhard LLP Notes Release of New Study Tying Elevated Metal Ions to Metal-on-Metal Hip Failure 2Health News:DePuy Pinnacle Hip Lawsuit News: Bernstein Liebhard LLP Notes Release of New Study Tying Elevated Metal Ions to Metal-on-Metal Hip Failure 3Health News:DePuy Pinnacle Hip Lawsuit News: Bernstein Liebhard LLP Notes Release of New Study Tying Elevated Metal Ions to Metal-on-Metal Hip Failure 4
(Date:7/11/2014)... July 11, 2014 Researchers have pioneered a ... The new technology, called Virtual Finger, allows scientists ... like neurons and synapses using the flat surface ... makes 3D imaging studies orders of magnitude more ... unprecedented level across many areas of experimental biology. ...
(Date:7/11/2014)... hippocampus, the marginal division of the striatum is ... the impact degree of substance P in the ... Yan Yu and his team, College of Biophotonics, ... staining, that substance P receptor, neurokinin 1 was ... division of normal rats. Unilateral or bilateral injection ...
(Date:7/11/2014)... , July 11, 2014 Research and ... "International Biometrics Technology Market - Industry Analysis Size Share ... their offering. http://photos.prnewswire.com/prnh/20130307/600769 ... crimes has created a need for high level security ... for personnel authentication such as username and passwords, tokens ...
Breaking Biology News(10 mins):Virtual finger enables scientists to navigate and analyze complex 3D images 2International Biometrics Technology Market - Industry Analysis Size Share Growth Trends and Forecast to 2019 2
Other Contents